Trial Profile
A Multicenter Phase III Uncontrolled Open-label Trial to Evaluate Safety and Efficacy of BAY81-8973 in Children With Severe Hemophilia A Under Prophylaxis Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Feb 2022
Price :
$35
*
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Acronyms LEOPOLD Kids
- Sponsors Bayer
- 08 Dec 2020 Results evaluating the efficacy and safety outcomes of patients with hemophilia A who were receiving FVIII-FS prior to enrolling into the LEOPOLD I and LEOPOLD KIDS clinical studies, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
- 10 Nov 2020 This trial has been completed in Ireland and Sweden (Global End Date: 27 Oct 2020), according to the European Clinical Trial Database record.
- 06 Nov 2020 Status changed from active, no longer recruiting to completed.